Thermodynamic inhibitors are estimated at 39.0% of inhibitor type demand in 2026, while methanol is projected at 32.0% of chemistry demand. Subsea flowlines are expected to account for 33.0% of application demand because cold pressurized transport sustains treatment needs despite qualification and chemical-volume constraints.